Share on LinkedInShare on LinkedIn

ARTICLE · 03 SEPTEMBER 2012

FTC Sights Set On Pharma Deals – Calls For Additional Hart-Scott-Rodino Reporting

Proskauer Rose LLP
Proskauer Rose LLP
Contributor
Proskauer Rose LLP

Proskauer Rose LLP

Firm Overview Proskauer is an elite global law firm with more than 900 lawyers across key financial...

View firm profile
Explore more from Proskauer Rose LLP

The Federal Trade Commission has proposed expanding Hart-Scott-Rodino reporting and waiting period obligations for certain pharmaceutical, biologics and medicine manufacturing licenses.

United StatesAntitrust/Competition Law

The Federal Trade Commission has proposed expanding Hart-Scott-Rodino reporting and waiting period obligations for certain pharmaceutical, biologics and medicine manufacturing licenses. The new rules are subject to public comment and would not take effect until later this year, but could impact transactions currently underway. According to the agency, an estimated 30 transactions per year presently not subject to reporting will be captured by the proposed rule change.

Under the HSR Act, certain stock or asset acquisitions are subject to notification and waiting period requirements prior to consummation to allow antitrust enforcers to evaluate potential anticompetitive effects. Patent transfers or assignments are treated as asset acquisitions under the HSR Act and are potentially reportable, but it has not always been clear when an exclusive patent license qualifies as an acquisition of an asset for HSR purposes.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from